Editorial: A miracle cure for stem cell conflicts
By Sacramento Bee,
Sacramento Bee
| 07. 10. 2005
As many readers know, leaders of California's stem cell research institute have steadfastly refused to disclose the stock holdings and consulting relationships of scientists who will be recommending billions in research grants over the next decade.
The official explanation? Institute Chairman Robert Klein II and interim president Zach Hall claim that top scientists will refuse to "volunteer" for the institute's grant review panel (which pays $300 a day) if they are forced to publicly disclose their potential conflicts.
This page has spent weeks examining this claim. Frankly, it is a bunch of malarkey.
Throughout the scientific world, stem cell researchers are increasingly disclosing their corporate research relationships and stock holdings.
Some must do so if they want to serve as faculty on Continuing Medical Education courses sponsored by the Johns Hopkins School of Medicine and other medical schools.
Others must publicly disclose conflicts when their research is published in the New England Journal of Medicine, the Journal of the American Medical Association and other prestigious publications.
Consider the recent meeting of the International Society for Stem Cell Research, held in...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...